Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 ± SYH2051 ± bevacizumab in advanced solid tumors (Phase Ib/II)
ChiCTR2500100723Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CPO301, SYH2051, bevacizumab in Nonhematologic neoplasms, sponsored by Sun Yat-sen University Cancer Center. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
CPO301SYH2051bevacizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500100723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100723.